SAN FRANCISCO, Nov. 28 – Millennium Pharmaceuticals on Tuesday announced it had begun Phase I clinical trials for its first molecule directed against a genomically- derived target for metabolic disease.

The compound, called MLN4760, was synthesized by Millennium and was designed with the hope of providing a treatment for obesity. Millennium, based in Cambridge, Mass., partnered with Abbott Park, Ill.-based Abbott Laboratories in the development of the drug.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.